The use of nimodipine (Nimotop-Bayer) in patients with chronic ischemic cerebral vasculopathies. Twenty-eight case reports.

Nimodipine therapy (30 mg x 3/die) was commenced in twenty-eight patients affected by chronic ischemic cerebral vasculopathies and continued for the 90 days in order to evaluate drug efficacy. Clinical controls were carried out 4, 8 and 12 weeks after the start of therapy using Doppler, ultrasound and neurological tests (the letter based on the SCAG neurological scale). Hemodynamic and hematochemical parameters were also monitored and controlled.

Ambroxol for prophylaxis and treatment of bronchopulmonary complications after chest surgery.

A double-blind clinical trial has been carried out with 40 patients hospitalized for thoracic pathology requiring surgery (cancer of the lungs, hamartoma, pleural mesothelioma, bullous dystrophy or emphysema of the lung). The purpose was to determine the effectiveness of the drug in preventing and in treating postoperative bronchopulmonary complications. The results showed that the patients treated with 1g of ambroxol for three days before surgery, on the day of the operation and for five days afterwards had a more rapid turnover of intra-alveolar surface tension and better re-expansion of the pulmonary parenchyma after surgery. They also had better mucociliary clearance of the respiratory tract. These improvements are indispensable for limiting bronchopulmonary complications after chest surgery.

[Indications for permanent electric electrostimulation in atrioventricular block]. / Indicazione all'elettrostimolazione elettrica permanente nei BAV.

Personal experience of pacemakers in patients suffering from (symptomatic and asymptomatic) 2nd degree AVB and 3rd degree AVB is reported.

High prevalence of nodular thyroid disease in patients with Cushing's disease.

OBJECTIVES: In the recent past, we have noted a frequent occurrence of thyroid nodules in our patients with Cushing's disease. We therefore elected to evaluate thyroid structure and function in these patients and also in patients with Cushing's syndrome of primary adrenal origin. PATIENTS AND METHODS: In 33 of the 37 patients (30 women and 3 men aged 19-66 years) with endogenous hypercortisolism referred to our Institution during the last five years, measurement of T4, T3, FT4, FT3, TSH serum levels and thyroid ultrasonography were performed, at first admission in 15 cases and subsequently in the course of follow-up in 18 cases. At the time of the study, 16 of the 33 patients had active Cushing's disease while 9 were in remission after successful surgery, 6 patients had an adrenal tumour and 2 patients had previously undergone unilateral adrenalectomy for an adrenal adenoma. Thyroid function and ultrasonography were also evaluated in 55 normal subjects, 40 women and 15 men aged 20-73 years. RESULTS: In 25 patients with Cushing's disease, we found a significantly higher prevalence of thyroid nodular disease than that recorded in 55 control subjects (60.0 vs 20.0%, chi 2 = 10.779, P < 0.005) and comparable to that in patients with active disease (56.2%) and those in remission (66.6%). Multiple nodules were present in 8 Cushing's patients and in 4 normal subjects while a single nodule was detected in 7 patients and in 7 controls. A markedly lower occurrence of thyroid abnormality was found in the 8 patients with adrenal tumours (25.0%, NS vs controls). In 9/17 (52.9%) patients with ultrasonographic evidence of thyroid nodules, these were palpable. As expected, serum thyroid hormone and TSH levels were reduced in patients with active Cushing's syndrome compared to normal controls. CONCLUSIONS: We found a significantly higher prevalence of nodular thyroid disease in patients with Cushing's disease with respect to a group of controls in whom the prevalence of thyroid nodules was comparable to that reported for the general population in Europe. The possibility that glucocorticoid excess is responsible for the development of thyroid changes does not seem likely since in our small series of patients with adrenal tumours the prevalence was only slightly higher than that observed in control subjects. Other factors related to hyperactivity of the corticotrophic cell, or a growth factor stimulating both corticotroph and thyrocyte proliferation might be involved. Evaluation of a larger series of patients with adrenal tumours may help to distinguish between these possibilities.